var data={"title":"Morphine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Morphine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390076?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=morphine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Morphine: Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=morphine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Morphine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50711535\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opioid Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada, in collaboration with manufacturers, will update the Canadian labelling of all prescription opioid products to include the following:</p>\n        <ul>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation for a daily opioid threshold dose for the management of chronic noncancer, nonpalliative pain (which aims to reduce risks of adverse events and overdoses associated with higher doses of opioids);</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Recommendation to limit the quantity of opioids prescribed for acute pain (which aims to reduce the duration of use and associated risks of developing dependence and substance use disorder); and</p></li>\n          <li>\n            <p style=\"text-indent:0em;\">Clarification of warnings, including those for special populations such as pregnant women and patients with a history of dependence or substance use disorder.</p></li></ul>\n        <p style=\"text-indent:0em;\">Health Canada has prioritized product tables for updating based on risk. The labelling updates for all prescription opioids are expected to be completed in January 2019.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65362a-eng.php.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">FDA Extends Expiration Dates for Certain Meridian Autoinjectors: Updated</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is alerting health care providers and emergency responders that certain lots of <i>AtroPen</i> (atropine), <i>CANA</i> (diazepam), morphine sulfate, and pralidoxime chloride autoinjectors manufactured by Meridian Medical Technologies can be used beyond the labeled expiration date, which should help mitigate potential shortages of these drugs. To ensure patient safety, products should be stored under the manufacturer&rsquo;s labeled storage conditions.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Additional information may be found at <a target=\"_blank\" href=\"http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB+DS1QnG3nll2ktzEV1bFFqNvp/S6dk6auUFKQXeUZdHA==&amp;TOPIC_ID=9788\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775511\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks with neuroaxial administration (Infumorph, Duramorph):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the risk of severe adverse effects when the epidural or intrathecal route of administration is employed, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose. Single-dose Duramorph neuraxial administration may result in acute or delayed respiratory depression for up to 24 hours. Monitor patients receiving Infumorph, as appropriate, for the first several days after catheter implantation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Ethanol use (extended-release capsules):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Instruct patients not to consume alcoholic beverages or use prescription or nonprescription products that contain alcohol while taking morphine extended-release (ER) capsules. The coingestion of alcohol with morphine ER may result in increased plasma levels and a potentially fatal overdose of morphine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Addiction, abuse, and misuse:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Morphine exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing morphine and monitor all patients regularly for the development of these behaviors and conditions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Life-threatening respiratory depression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious, life-threatening, or fatal respiratory depression may occur with use of morphine. Monitor for respiratory depression, especially during initiation of morphine or following a dose increase. Swallow morphine ER formulations whole. ER capsule contents may be sprinkled on applesauce and swallowed immediately without chewing. Crushing, chewing, or dissolving the tablets or contents within the capsule can cause rapid release and absorption of a potentially fatal dose of morphine. Because of delay in maximum CNS effect with IV administration (30 minutes), rapid IV administration may result in overdosing. Observe patients in a fully equipped and staffed environment for at least 24 hours after each test dose of Infumorph and, as indicated, for the first several days after surgery.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonatal opioid withdrawal syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Prolonged use of morphine during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Accidental ingestion (oral formulations):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Accidental ingestion of even one dose of morphine, especially by children, can result in a fatal overdose of morphine.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risk of medication errors (oral solution):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ensure accuracy when prescribing, dispensing, and administering morphine oral solution. Dosing errors due to confusion between mg and mL, and other morphine solutions of different concentrations, can result in accidental overdose and death</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with benzodiazepines or other CNS depressants:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of morphine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776636\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Arymo ER;</li>\n      <li>AVINza [DSC];</li>\n      <li>Duramorph;</li>\n      <li>Infumorph 200;</li>\n      <li>Infumorph 500;</li>\n      <li>Kadian;</li>\n      <li>MorphaBond ER;</li>\n      <li>MS Contin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776637\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Doloral;</li>\n      <li>Kadian;</li>\n      <li>M-Eslon;</li>\n      <li>M.O.S. 10;</li>\n      <li>M.O.S. 20;</li>\n      <li>M.O.S. 30;</li>\n      <li>M.O.S.-SR;</li>\n      <li>M.O.S.-Sulfate;</li>\n      <li>Morphine Extra Forte Injection;</li>\n      <li>Morphine Forte Injection;</li>\n      <li>Morphine HP;</li>\n      <li>Morphine LP Epidural;</li>\n      <li>Morphine SR;</li>\n      <li>Morphine-EPD;</li>\n      <li>MS Contin;</li>\n      <li>MS Contin SRT;</li>\n      <li>MS-IR;</li>\n      <li>Novo-Morphine SR;</li>\n      <li>PMS-Morphine Sulfate SR;</li>\n      <li>ratio-Morphine;</li>\n      <li>ratio-Morphine SR;</li>\n      <li>Sandoz-Morphine SR;</li>\n      <li>Statex;</li>\n      <li>Teva-Morphine SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776648\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Opioid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776811\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">These are guidelines and do not represent the doses that may be required in all patients. Doses and dosage intervals should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b> Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM, SubQ: </i>\n      <b>Note:</b> Repeated SubQ administration causes local tissue irritation, pain, and induration. The use of IM injections is no longer recommended especially for repeated administration due to painful administration, variable absorption and lag time to peak effect; other routes are more reliable and less painful (APS, 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: Opioid naive: 5 to 10 mg every 4 hours as needed; usual dosage range: 5 to 15 mg every 4 hours as needed. Patients with prior opioid exposure may require higher initial doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> Initial: Opioid naive: 2.5 to 5 mg every 3 to 4 hours; patients with prior opioid exposure may require higher initial doses. <b>Note:</b> Administration of 2 to 3 mg every 5 minutes until pain relief or if associated sedation, oxygen saturation &lt;95%, or serious adverse event occurs may be appropriate in treating acute moderate to severe pain in settings such as the immediate postoperative period or the emergency department (Aubrun, 2012; Lvovschi, 2008); dose reduction in the immediate postoperative period (postanesthesia care unit) in the elderly is usually not necessary (Aubrun, 2002). A maximum cumulative dose (eg, 10 mg) prompting reevaluation of continued morphine use and/or dose should be included as part of any medication order intended for short-term use (eg, PACU orders). Refer to institution-specific protocols as appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Acute myocardial infarction, analgesia (off-label dose): Initial management: 4 to 8 mg (lower doses in elderly patients); subsequently may give 2 to 8 mg every 5 to 15 minutes as needed (O'Gara, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Critically ill patients, analgesia (off-label dose): 2 to 4 mg every 1 to 2 hours <b>or</b> 4 to 8 mg every 3 to 4 hours as needed (Barr, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV, SubQ continuous infusion:</i> Opioid tolerant: 0.8 to 10 mg/hour; usual range: 20 to 50 mg/hour (higher doses have been reported) (Citron 1984). <b>Note:</b> May administer a loading dose (amount administered should depend on severity of pain) prior to initiating the infusion. A continuous (basal) infusion is not recommended in an opioid-naive patient (ISMP 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion for critically ill patients: Usual dosage range: 2 to 30 mg/hour (Barr, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patient-controlled analgesia (PCA) (APS, 2008): <b>Note:</b> In opioid-naive patients, consider lower end of dosing range:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Usual concentration: 1 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Demand dose: Usual: 1 mg; range: 0.5 to 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Lockout interval: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Epidural:</i> <b>Note: Must use preservative-free (PF) formulation indicated for epidural use. </b> Administer with extreme caution and in reduced dosage to geriatric or debilitated patients. Vigilant monitoring is particularly important in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Single dose (using 0.5 or 1 mg/mL PF solution): <b>Lumbar region:</b> 30 to 100 mcg/kg (optimal range: 2.5 to 3.75 mg; may depend upon patient comorbidities) (Bujedo 2012; Sultan 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion (using 0.5 or 1 mg/mL PF solution; may be combined with bupivacaine): 0.2 to 0.4 mg/hour (Bujedo 2012; Mahoney 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous microinfusion (using 10 mg/mL or 25 mg/mL PF solution; may require dilution):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Opioid naive: Initial: 3.5 to 7.5 mg over 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Opioid tolerant: Initial: 4.5 to 10 mg over 24 hours, titrate to effect; usual maximum is ~30 mg per 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intrathecal:</i> <b>Note: Must use preservative-free (PF) formulation indicated for intrathecal use. </b>Administer with extreme caution and in reduced dosage to geriatric or debilitated patients. Intrathecal dose is usually <sup>1</sup>/<sub>10</sub> (one-tenth) that of epidural dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Opioid naive:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Single dose (using 0.5 or 1 mg/mL PF solution): Lumbar region:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer's labeling: 0.2 to 1 mg may provide satisfactory pain relief for up to 24 hours. (Caution: This is only 0.4 to 2 mL of the 0.5 mg/mL potency or 0.2 to 1 mL of the 1 mg/mL potency.) Do not inject intrathecally more than 2 mL of the 0.5 mg/mL potency or 1 mL of the 1 mg/mL potency; repeat doses are not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternative recommendations: 0.1 to 0.3 mg (may provide adequate relief for up to 24 hours; APS, 2008); repeat doses are <b>not</b> recommended. If pain recurs within 24 hours of administration, use of an alternate route of administration is recommended. <b>Note:</b> Although product labeling recommends doses up to 1 mg, an analgesic ceiling exists with doses &gt;0.3 mg and the risk of respiratory depression is higher with doses &gt;0.3 mg (Rathmell 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous microinfusion (using 10 mg/mL or 25 mg/mL PF solution; may require dilution): Lumbar region: Initial: 0.2 to 1 mg over 24 hours only after initial in-hospital evaluation of response to single-dose injections using morphine 0.5 or 1 mg/mL PF solution.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Opioid tolerant: Continuous microinfusion (using 10 mg/mL or 25 mg/mL PF solution; may require dilution]): Lumbar region: Dosage range: 1 to 10 mg over 24 hours, titrate to effect; usual maximum is ~20 mg over 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> Limited experience with continuous intrathecal infusion of morphine has shown that the daily doses have to be increased over time. Employ doses &gt;20 mg/day with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral (immediate-release formulations):</i> Opioid naive: Initial: <b>Note:</b> Usual dosage range: 10 to 30 mg every 4 hours as needed. Patients with prior opioid exposure may require higher initial doses.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: 10 to 20 mg every 4 hours as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablet: 15 to 30 mg every 4 hours as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral (extended-release formulations): </i> <b>Note:</b> Patients taking opioids chronically may become tolerant and require doses higher than the usual dosage range to maintain the desired effect. Tolerance can be managed by appropriate dose titration. There is no optimal or maximal dose for morphine in chronic pain. The appropriate dose is one that relieves pain throughout its dosing interval without causing unmanageable side effects. Consider total daily dose, potency, prior opioid use, degree of opioid experience and tolerance, conversion from previous opioid (including opioid formulation), patient&rsquo;s general condition, concurrent medications, and type and severity of pain during prescribing process. Opioid tolerance is defined as: Patients already taking at least 60 mg of oral morphine daily, 25 mcg transdermal fentanyl per hour, 30 mg of oral oxycodone daily, 8 mg oral hydromorphone daily, 25 mg of oral oxymorphone daily, 60 mg oral hydrocodone, or an equivalent dose of another opioid for at least 1 week.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">A patient's morphine requirement should be established using immediate-release formulations. Conversion to long-acting products may be considered when chronic, continuous treatment is required. Higher dosages should be reserved for use only in opioid-tolerant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsules, extended release (Avinza): Daily dose administered once daily (for best results, administer at same time each day). <b>Note:</b> Avinza 90 mg and 120 mg are only indicated for use in opioid-tolerant patents.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Use as the first opioid analgesic or use in patients who are <b>not</b> opioid tolerant: Initial: 30 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Titration and maintenance: Adjust in increments &le;30 mg daily every 3 to 4 days. Maximum: 1600 mg daily due to fumaric acid content.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsules, extended release (Kadian): <b>Note:</b> Kadian 100 and 200 mg and a total daily dose &gt;120 mg are only for use in opioid-tolerant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Use as the first opioid analgesic: Has not been evaluated. Use an immediate-release morphine formulation and then convert patients to Kadian in the same fashion as initiating therapy in a nonopioid-tolerant patient.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Use in patients who are <b>not</b> opioid tolerant: Initial: 30 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Titration and maintenance: Dose adjustments may be done every 1 to 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablets, extended release (Arymo ER):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Use as the first opioid analgesic or in patients who are <b>not</b> opioid tolerant: Initial: 15 mg every 8 to 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Titration and maintenance: Dose adjustments may be done every 1 to 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablets, extended release (MorphaBond ER):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Use as the first opioid analgesic or who are <b>not</b> opioid tolerant: Initial: 15 mg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Titration and maintenance: Dose adjustments may be done every 1 to 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablets, extended release (MS Contin): <b>Note:</b> MS Contin 100 mg and 200 mg tablets are only for use in opioid-tolerant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Use as the first opioid analgesic: Initial: 15 mg every 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Use in patients who are <b>not</b> opioid tolerant: Initial: 15 mg every 12 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Titration and maintenance: Dose adjustments may be done every 1 to 2 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Rectal:</i> 10 to 20 mg every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Conversion from other oral morphine formulations to extended-release formulations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Arymo ER, MS Contin:</i> Total daily oral morphine dose may be administered either in 2 divided doses daily (every 12 hours) <b>or</b> in 3 divided doses (every 8 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Avinza:</i> Total daily morphine dose administered once daily. The first dose of Avinza may be taken with the last dose of the immediate-release morphine. Maximum: 1,600 mg daily due to fumaric acid content.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Kadian:</i> Total daily oral morphine dose may be either administered once daily or in 2 divided doses daily (every 12 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MorphaBond ER:</i> Total daily oral morphine dose administered in 2 divided doses (every 12 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from parenteral morphine or other opioids to extended-release formulations: Substantial interpatient variability exists in relative potency. Therefore, it is safer to underestimate a patient's daily oral morphine requirement and provide breakthrough pain relief with immediate-release morphine than to overestimate requirements. Consider the parenteral to oral morphine ratio or other oral or parenteral opioids to oral morphine conversions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Parenteral to oral morphine ratio: Between 2 to 6 mg of oral morphine may be required for analgesia equivalent to 1 mg of parenteral morphine. An oral dose 3 times the daily parenteral dose may be sufficient in chronic pain settings.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Other parenteral or oral nonmorphine opioids to oral morphine: Specific recommendations are not available; refer to published relative potency data realizing that such ratios are only approximations. In general, it is safest to administer 50% of the estimated daily morphine requirement as the initial dose, and to manage inadequate analgesia by supplementation with immediate-release morphine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Conversion from methadone to extended-release formulations: Close monitoring is required when converting methadone to another opioid. Ratio between methadone and other opioid agonists varies widely according to previous dose exposure. Methadone has a long half-life and can accumulate in the plasma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Discontinuation of oral formulations: Decrease dose by 25% to 50% every 2 to 4 days; monitor carefully for signs/symptoms of withdrawal. If patient displays withdrawal symptoms, increase dose to previous dose and then reduce dose more slowly by increasing interval between dose reductions, decreasing amount of daily dose reduction, or both.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776810\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=morphine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Morphine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">These are guidelines and do not represent the doses that may be required in all patients. Doses and dosage intervals should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute pain (moderate to severe): Note:</b> The use of IM injections is no longer recommended, especially for repeated administration due to painful administration, variable absorption, and lag time to peak effect; other routes are more reliable and less painful (American Pain Society 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants &le;6 months, nonventilated:</i> <b>Note:</b> Infants &lt;3 months of age are more susceptible to respiratory depression; lower doses are recommended (American Pain Society 2008):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Oral solution (2 mg/mL or 4 mg/mL): 0.08 to 0.1 mg/kg/dose every 3 to 4 hours (American Pain Society 2008; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV or SubQ: 0.025 to 0.03 mg/kg/dose every 2 to 4 hours as needed (American Pain Society 2008; Berde 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Infants &gt;6 months, Children, and Adolescents:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Immediate-release tablets, oral solution (2 mg/mL or 4 mg/mL):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;50 kg: 0.2 to 0.5 mg/kg/dose every 3 to 4 hours as needed; some experts have recommended an initial dose of 0.3 mg/kg for severe pain; usual initial maximum dose: 15 to 20 mg (American Pain Society 2008; APA 2012; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;50 kg: 15 to 20 mg every 3 to 4 hours as needed (American Pain Society 2008; Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV, or SubQ; intermittent dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;50 kg: Initial: 0.05 mg/kg/dose; usual range: 0.1 to 0.2 mg/kg/dose every 2 to 4 hours as needed; usual maximum dose: Infants: 2 mg/dose; Children 1 to 6 years: 4 mg/dose; Children 7 to 12 years: 8 mg/dose; Adolescents: 10 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;50 kg: Initial: 2 to 5 mg every 2 to 4 hours as needed; higher doses have been recommended (5 to 8 mg every 2 to 4 hours as needed) and may be needed in tolerant patients (Berde 2002; Kliegman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion, SubQ continuous infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &lt;50 kg: Initial: 0.01 mg/kg/hour (10 mcg/kg/hour); titrate carefully to effect; dosage range: 0.01 to 0.04 <b>mg</b>/kg/<b>hour</b> (10 to 40 mcg/kg/<b>hour</b>) (APA 2012; Friedrichsdorf 2007; Golianu 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patient weight &ge;50 kg: 1.5 mg/<b>hour</b> (Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Conversion from intermittent IV morphine: Administer the patient's total daily IV morphine dose over 24 hours as a continuous infusion; titrate dose to appropriate effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Analgesia for minor procedures/sedation:</b> Infants, Children, and Adolescents: IV: 0.05 to 0.1 mg/kg/dose; administer 5 minutes before the procedure; maximum dose: 4 mg; may repeat dose in 5 minutes if necessary (Cramton 2012; Zeltzer 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Patient-controlled analgesia (PCA), opioid-naive: Note:</b> All patients should receive an initial loading dose of an analgesic (to attain adequate control of pain) before starting PCA for maintenance. Adjust doses, lockouts, and limits based on required loading dose, age, state of health, and presence of opioid tolerance. Use lower end of dosing range for opioid-na&iuml;ve. Assess patient and pain control at regular intervals and adjust settings if needed (American Pain Society 2008): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents, weighing &lt;50 kg: <b>Note:</b> PCA has been used in children as young as 5 years of age; however, clinicians need to assess children 5 to 8 years of age to determine if they are able to use the PCA device correctly (American Pain Society 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual concentration: 1 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Demand dose: Usual initial: 0.02 mg/kg/dose; usual range: 0.01 to 0.03 mg/kg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lockout: Usual initial: 5 doses/hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lockout interval: Range: 6 to 8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual basal rate: 0 to 0.03 mg/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;5 years and Adolescents, weighing &ge;50 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Usual concentration: 1 mg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Demand dose: Usual initial: 1 mg; usual range: 0.5 to 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Lockout interval: Usual initial: 6 minutes; usual range: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management: </b>\n      <b>Tablets, extended release (MS Contin) (</b>\n      <b>off-label use): Note:</b> Patients taking chronic opioids may become tolerant and require higher-than-usual doses to maintain the desired effect. Tolerance can be managed by appropriate dose titration. There is no optimal/maximal dose for morphine in chronic pain. An appropriate dose relieves pain throughout the dosing interval while avoiding unmanageable side effects. Consider total daily dose, potency, prior opioid use, degree of opioid experience and tolerance, conversion from previous opioid (including opioid formulation), patient's general condition, concurrent medications, and type/severity of pain during prescribing process. For extended-/controlled-release preparations, morphine requirement should be established using immediate-release formulations; conversion to long acting products may be considered when chronic, continuous treatment is required. Higher dosages should be reserved for use only in opioid-tolerant patients. Do not discontinue abruptly; gradually titrate dose downward (eg, every 2 to 4 days). Due to more rapid clearance, a sustained-release morphine formulation dosed every 12 hours in adults may require every-8-hour dosing in children (Berde 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Analgesia: </b>Children and Adolescents able to swallow tablets whole: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">20 to &lt;35 kg: Suggested initial dose: 15 mg every 8 to 12 hours (Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">35 to &lt;50 kg: Suggested initial dose: 15 to 30 mg every 8 to 12 hours (Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;50 kg: Suggested initial dose: 30 to 45 mg every 8 to 12 hours (Berde 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cancer-related pain:</b> Children and Adolescents able to swallow tablets whole: Oral: 0.3 to 0.6 mg/kg/dose every 12 hours (Berde 1990)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776812\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Use with caution; may require reduced dosage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776813\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">According to the manufacturer's labeling, no specific dosage adjustments are provided (all formulations). In general, the manufacturers recommend starting cautiously with lower doses; titrating slowly while carefully monitoring for side effects. However, the choice of an alternate opioid may be prudent in patients with baseline renal impairment or rapidly changing renal function especially since other analgesics may be safer and reduced initial morphine dosing may result in suboptimal analgesia.  Although clearance of morphine is similar to patients with normal renal function, glucuronide metabolites (M3G [inactive as an analgesic; may contribute to CNS stimulation] and M6G [active analgesic]) accumulate in renal impairment resulting in increased sensitivity; patients may experience severe and prolonged respiratory depression which may even be delayed (Lugo 2002; Niscola 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776814\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer's labeling. Pharmacokinetics unchanged in mild liver disease; substantial extrahepatic metabolism may occur. In cirrhosis, increases in half-life and AUC suggest dosage adjustment required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776907\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 30 mg [DSC] [contains fd&amp;c yellow #10 (quinoline yellow), fumaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 45 mg [DSC] [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 60 mg [DSC] [contains fumaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 75 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 90 mg [DSC] [contains fd&amp;c red #40, fumaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AVINza: 120 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fumaric acid]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 20 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 30 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 40 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 50 mg, 60 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 70 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 80 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 100 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 130 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 150 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kadian: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 30 mg, 45 mg, 50 mg, 60 mg, 75 mg, 80 mg, 90 mg, 100 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Device, Intramuscular, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/0.7 mL (0.7 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (1 mL [DSC]); 8 mg/mL (1 mL [DSC]); 10 mg/mL (1 mL [DSC], 10 mL [DSC]); 15 mg/mL (1 mL [DSC], 20 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duramorph: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infumorph 200: 200 mg/20 mL (10 mg/mL) (20 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infumorph 500: 500 mg/20 mL (25 mg/mL) (20 mL) [antioxidant free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/mL (10 mL); 1 mg/mL (10 mL); 2 mg/mL (1 mL); 4 mg/mL (1 mL); 5 mg/mL (1 mL); 8 mg/mL (1 mL); 10 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (10 mL [DSC], 30 mL); 25 mg/mL (4 mL [DSC], 10 mL [DSC]); 50 mg/mL (20 mL, 50 mL); 1000 mg/100 mL (100 mL); 150 mg/150 mL in NaCl 0.9% (150 mL); 2,500 mg/250 mL in NaCl 0.9% (250 mL); 250 mg/250 mL in Dextrose 5% (250 mL); 250 mg/250 mL in NaCl 0.9% (250 mL); 250 mg/50 mL in NaCl 0.9% (50 mL); 50 mg/50 mL (50 mL); 500 mg/100 mL in NaCl 0.9% (100 mL); 500 mg/250 mL in NaCl 0.9% (250 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (30 mL); 2 mg/mL (1 mL); 4 mg/mL (1 mL); 150 mg/30 mL (30 mL); 8 mg/mL (1 mL); 10 mg/mL (1 mL); 15 mg/mL (1 mL [DSC]); 25 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/5 mL (5 mL, 15 mL, 100 mL, 500 mL); 20 mg/5 mL (5 mL, 100 mL, 500 mL); 20 mg/mL (30 mL, 120 mL); 100 mg/5 mL (15 mL, 30 mL, 120 mL, 240 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/mL (1 mL); 150 mg/30 mL in NaCl 0.9% (30 mL); 2 mg/2 mL in NaCl 0.9% (2 mL); 275 mg/55 mL in NaCl 0.9% (55 mL); 5 mg/5 mL in NaCl 0.9% (5 mL); 50 mg/25 mL in Dextrose 5% (25 mL); 50 mg/50 mL (50 mL); 60 mg/30 mL in NaCl 0.9% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppository, Rectal, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg (12 ea); 10 mg (12 ea); 20 mg (12 ea); 30 mg (12 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 30 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet ER 12 Hour Abuse-Deterrent, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MorphaBond ER: 15 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MorphaBond ER: 30 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MorphaBond ER: 60 mg [contains fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MorphaBond ER: 100 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 15 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 30 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 60 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MS Contin: 200 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 30 mg, 60 mg, 100 mg, 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release Abuse-Deterrent, Oral, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arymo ER: 15 mg (100 ea); 30 mg (100 ea) [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Arymo ER: 60 mg (100 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776646\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776908\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, oral, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Doloral: 1 mg/mL (10 mL, 250 mL, 500 mL); 5 mg/mL (10 mL, 250 mL, 500 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776634\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9845085\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AVINza: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM311346.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WfLLbuiSptjHFvx0tBMz99w==&amp;TOPIC_ID=9788\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM311346.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kadian:<a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020616s057lbl.pdf#page=33&amp;token=X+Qadbu+uicdz0daAyMxYka/8clP0SQ/uUAH41cn84OmPa25HU0uSHsazJdIaTVaQzkBJ02CFJuMOJlYxUMFFlbDJLj48S3WvBmaftwInJQ+QcjW8HWc3UsB3vCiJw13&amp;TOPIC_ID=9788\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020616s057lbl.pdf#page=33</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MorphaBond: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206544s002s005lbl.pdf#page=34&amp;token=UwXgf47ybr+yCVG1bBZq+T+JU9oPg80u4dp9/g/tQjDzqJF/a1pIeaKLThF5Ssf3TsPPeBuGbmZCRWvSKZGGIAmYQPZA9FsIDwtjwPg+gCDfYhfj004Y3VEl9jK3Uui3&amp;TOPIC_ID=9788\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206544s002s005lbl.pdf#page=34</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MS Contin: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM311374.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WBLbgrqQDKO3cCTU5ToIPnA==&amp;TOPIC_ID=9788\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM311374.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201517s009lbl.pdf#page=26&amp;token=m+FA7jwtgxoYKyM9u9rVS45+tptraUDNDVYY+hrPoJDIdq172kCZOO5tNQEf18Mc0QMdmtKs/Xp3WtQKdpfEkcRv92TkLdrzdAVwsOCsMR+MmmFIfC9pwLaphEsWmE7U&amp;TOPIC_ID=9788\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201517s009lbl.pdf#page=26</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776887\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Do not crush, chew, or dissolve extended release (ER) formulations; swallow whole. Cutting, breaking, crushing, chewing, or dissolving ER formulations may result in uncontrolled delivery of morphine, leading to overdose and death.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Avinza, Kadian: Capsules may be opened and sprinkled on applesauce and eaten immediately without chewing; do not crush, dissolve, or chew the beads, as it can result in a rapid release of a potentially fatal dose of morphine. Ensure all pellets have been swallowed by rinsing mouth. Contents of Kadian capsules may be opened and sprinkled over 10 mL water and flushed through prewetted 16F gastrostomy tube; do not administer Kadian through gastric/nasogastric tubes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Arymo ER: Swallow tablets whole, one tablet at a time, with enough water to ensure complete swallowing immediately after placing in the mouth; do not pre-soak, lick, or wet tablets prior to placing in the mouth.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer single-use prefilled syringes/cartridges via slow IV push over 4 to 5 minutes (rapid administration may result in chest wall rigidity). Concentrated vials are available for preparation of continuous IV infusion or PCA; refer to indication-specific infusion rates in dosing for detailed recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epidural, intrathecal: Use only preservative-free solutions indicated for intrathecal or epidural use; refer to indication-specific infusion rates in dosing for detailed recommendations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472937\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472938\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.1 mg/mL, 0.5 mg/mL, <b>or</b> 1 mg/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776698\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pain management:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Preservative-free solutions only: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Duramorph: </i>Epidural or intrathecal management of pain without attendant loss of motor, sensory, or sympathetic function. <b>Note:</b> Not for use in continuous microinfusion devices.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Infumorph:</i> Used in continuous microinfusion devices for intrathecal or epidural administration in management of intractable chronic pain severe enough to require an opioid analgesic and for which less invasive means of controlling pain are inadequate. <b>Note:</b> Not for single-dose IV, IM, or subcutaneous administration or single-dose neuraxial injection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended-release:  </i>Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Immediate-release:</i>  Management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oral solution 100 mg per 5 mL (20 mg/mL) is for opioid-tolerant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Reserve morphine for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ER formulations are not indicated as as-needed analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe pain: </b>  Rectal: Relief of severe chronic and acute pain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8775520\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Morphine may be confused with HYDROmorphone, methadone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Morphine sulfate may be confused with magnesium sulfate</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Kadian may be confused with Kapidex [DSC]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">MS Contin may be confused with OxyCONTIN</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">MSO<sub>4</sub> and MS are error-prone abbreviations (mistaken as magnesium sulfate)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">AVINza may be confused with Evista, INVanz</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Roxanol may be confused with OxyFast, Roxicet, Roxicodone</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Use care when prescribing and/or administering morphine solutions. These products are available in different concentrations. Always prescribe dosage in mg; <b>not</b> by volume (mL).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Use caution when selecting a morphine formulation for use in neurologic infusion pumps (eg, Medtronic delivery systems). The product should be appropriately labeled as &ldquo;preservative-free&rdquo; and suitable for intraspinal use via continuous infusion. In addition, the product should be formulated in a pH range that is compatible with the device operation specifications.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776722\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (oral: 9% to &gt;10%), headache (&lt;2% to &gt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (9% to &gt;10%), nausea (7% to &gt;10%), vomiting (2% to &gt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary retention (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (3% to 10%), chest pain (oral: 2%), atrial fibrillation (oral: &lt;2%), bradycardia (oral, rectal: &lt;2%), edema (oral, rectal: &lt;2%), facial flushing (oral, rectal: &lt;2%), flushing (oral: &lt;2%), hypertension (oral: &lt;2%), hypotension (oral: &lt;2%), palpitations (oral, rectal: &lt;2%), syncope (oral, rectal: &lt;2%), tachycardia (oral: &lt;2%), vasodilatation (oral: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression (oral: &lt;2% to 10%), insomnia (oral, rectal: &lt;2% to 10%), paresthesia (oral: &lt;2% to 10%), dizziness (6%), anxiety (&le;6%), abnormality in thinking (oral: &lt;5%), confusion (&lt;5%), seizure (&lt;5%), pain (oral: 3%), abnormal dreams (oral: &lt;2%), agitation (oral, rectal: &lt;2%), amnesia (oral: &lt;2%), apathy (oral: &lt;2%), ataxia (oral: &lt;2%), chills (oral: &lt;2%), decreased cough reflex (&lt;2%), euphoria (&lt;2%), hallucination (oral: &lt;2%), hypoesthesia (oral: &lt;2%), lack of concentration (oral: &lt;2%), lethargy (oral: &lt;2%), malaise (oral: &lt;2%), myoclonus (&lt;2%), slurred speech (oral: &lt;2%), vertigo (oral: &lt;2%), voice disorder (oral: &lt;2%), withdrawal syndrome (oral: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (oral, rectal: 3% to 10%), diaphoresis (oral, rectal: 2% to 10%), decubitus ulcer (oral: &lt;2%), pallor (oral: &lt;2%), pruritus (&lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Amenorrhea (oral: &lt;2%), decreased libido (oral, rectal: &lt;2%), gynecomastia (oral: &lt;2%), hyponatremia (oral: &lt;2%), SIADH (oral: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (oral: 3% to 10%), anorexia (oral, rectal: 3% to 10%), diarrhea (3% to 10%), xerostomia (oral, rectal: 3% to 10%), biliary colic (oral: &lt;2%), delayed gastric emptying (oral: &lt;2%), dyspepsia (oral: &lt;2%), dysphagia (oral: &lt;2%), gastric atony (oral: &lt;2%), gastroesophageal reflux disease (oral: &lt;2%), hiccups (oral: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Impotence (oral: &lt;2%), urinary hesitancy (oral, rectal: &lt;2%), urine abnormality (oral: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (oral: 2% to &lt;5%), thrombocytopenia (oral: &lt;5%), leukopenia (oral: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (oral: &lt;2% to 10%), tremor (oral: 2%), weakness (oral, rectal: &le;2%), arthralgia (oral: &lt;2%), bone pain (oral: &lt;2%), foot-drop (oral: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Amblyopia (oral: &lt;2%), blurred vision (oral: &lt;2%), conjunctivitis (oral: &lt;2%), diplopia (oral: &lt;2%), miosis (oral, IV: &lt;2%), nystagmus (oral: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (3% to 10%), flu-like symptoms (oral: &lt;2% to 10%), hypoventilation (&lt;5%), asthma (oral: &lt;2%), atelectasis (oral: &lt;2%), hypoxia (oral: &lt;2%), pulmonary edema (oral: &lt;2%; includes noncardiogenic), respiratory depression (IV, epidural, intrathecal: &lt;2%), respiratory insufficiency (oral: &lt;2%), rhinitis (oral: &lt;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (oral: 2% to 10%), fever (oral: 2% to 10%), increased severity of condition (oral: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Circulatory depression (oral, IV), orthostatic hypotension (IM, IV), peripheral vascular insufficiency (IV), phlebitis (IV), presyncope (oral, rectal), shock</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal gait (oral), altered mental status (IV), coma (oral), delirium (oral), disorientation (oral, rectal), disruption of body temperature regulation (IV, epidural, intrathecal), dysphoria, dyssynergia (oral), fear (IV), feeling abnormal (oral), increased catecholamines (IV, epidural, intrathecal), increased intracranial pressure (oral), mood changes (oral), nervousness (oral), paradoxical central nervous system stimulation (IV, epidural, intrathecal), sedation (oral, rectal), toxic psychosis (IM, IV, epidural, intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hemorrhagic urticaria (IV, rectal), urticaria, xeroderma (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Antidiuretic effect (oral, rectal), increased thirst (oral), weight loss (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Biliary tract spasm (rectal), decreased appetite (IV), dysgeusia (oral), gastroenteritis (oral), gastrointestinal hypermotility (IV; in patients with chronic ulcerative colitis), rectal disease (oral), toxic megacolon (IV; patients with chronic ulcerative colitis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria (oral), ejaculatory disorder (oral), erectile dysfunction (IV), hypogonadism (oral), oliguria, ureteral spasm (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Granuloma (IV, epidural, intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction (IM)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site (IV), induration at injection site (SC), local irritation (IV, epidural, intrathecal), local swelling (IV, intrathecal, epidural; genital swelling in males following infusion device implant surgery), pain at injection site (SC), residual mass at injection site (inflammatory; IV, epidural, intrathecal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Decreased bone mineral density (oral), laryngospasm (oral), muscle rigidity (oral), muscle spasm (IV, epidural, intrathecal; myoclonic spasm of lower extremities), muscle twitching (oral), vesicle sphincter spasm (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye pain (oral), visual disturbance (oral, rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea (oral, IV)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Impaired physical performance (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, bronchospasm, dehydration, difficulty thinking, fatigue, hyperalgesia, hypersensitivity reaction, hypertonia, increased serum prolactin (Molitch 2008; Vuong 2010), intestinal obstruction, sepsis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776704\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis) to morphine or any component of the formulation; significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; concurrent use of monoamine oxidase inhibitors (MAOIs) or use of MAOIs within the last 14 days; GI obstruction, including paralytic ileus (known or suspected).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for opioids is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Additional contraindications:</p>\n    <p style=\"text-indent:0em;margin-left:2em;\">Epidural/intrathecal: Infection at infusion site; concomitant anticoagulant therapy; uncontrolled bleeding diathesis; presence of any other concomitant therapy or medical condition that would render administration hazardous; upper airway obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: Severe CNS depression; cardiac arrhythmias, heart failure due to chronic lung disease; increased intracranial or cerebrospinal pressure, head injuries, brain tumor; acute alcoholism, delirium tremens; seizure disorder; use after biliary tract surgery, suspected surgical abdomen, surgical anastomosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Contraindications may vary per product labeling; refer also to product labels: Suspected surgical abdomen (eg, acute appendicitis, pancreatitis); disease/condition that affects bowel transit (known or suspected); chronic obstructive airway; status asthmaticus; management of acute pain, including use in outpatient or day surgeries; mild, intermittent, or short-duration pain that can be managed with other pain medications; acute respiratory depression; hypercarbia; cor pulmonale; acute alcoholism; delirium tremens; convulsive disorders; severe CNS depression; increased cerebrospinal; intracranial pressure; brain tumor; head injury; cardiac arrhythmias; pregnancy; use during labor and delivery; breastfeeding; toxic psychosis and severe kyphoscoliosis (Kadian 2015); severe cirrhosis (M-Ediat 2017); hypotension, (M-Eslon 2014), emotional instability and/or suicidal ideation (Statex 2016); surgical anastomosis (morphine sultafe inj Sandoz 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776705\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Some dosage forms may be contraindicated in patients with severe CNS depression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: May cause constipation which may be problematic in patients with unstable  angina and patients post-myocardial infarction. Consider preventive measures (eg, stool softener, increased fiber) to reduce the potential for constipation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause severe hypotension (including orthostatic hypotension and syncope); use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), circulatory shock, or drugs that may exaggerate hypotensive effects (including phenothiazines or general anesthetics). Monitor for symptoms of hypotension following initiation or dose titration. Avoid use in patients with circulatory shock. Some dosage forms may be contraindicated in patients with cardiac arrhythmias or heart failure due to chronic lung disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: <b>[US Boxed Warning]: Serious, life-threatening, or fatal respiratory depression may occur. Monitor closely for respiratory depression, especially during initiation or dose escalation. Swallow morphine ER formulations whole (or may sprinkle the contents of the  capsule on applesauce and swallow without chewing); crushing, chewing, or dissolving the ER formulations can cause rapid release and absorption of a potentially fatal dose of morphine.</b> Carbon dioxide retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenocortical insufficiency: Use with caution in patients with adrenal insufficiency, including Addison disease. Long-term opioid use may cause secondary hypogonadism, which may lead to sexual dysfunction, infertility, mood disorders, and osteoporosis (Brennan 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biliary tract impairment: Use with caution in patients with biliary tract dysfunction  or acute pancreatitis; opioids may cause constriction of sphincter of Oddi.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression/coma: Avoid use in patients with impaired consciousness or coma, as these patients are susceptible to intracranial effects of CO<sub>2</sub> retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delirium tremens: Use with caution in patients with delirium tremens. Some dosage forms may be contraindicated in patients with delirium tremens.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur. Some dosage forms may be contraindicated in patients with increased intracranial or cerebrospinal pressure, head injuries, or brain tumor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mental health conditions: Use opioids with caution for chronic pain in patients with mental health conditions (eg, depression, anxiety disorders, post-traumatic stress disorder) due to increased risk for opioid use disorder and overdose; more frequent monitoring is recommended (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obesity: Use with caution in patients who are morbidly obese.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Use with caution in patients with toxic psychosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution and monitor for respiratory depression in patients with significant chronic obstructive pulmonary disease or cor pulmonale and patients having a substantially decreased respiratory reserve, hypoxia, hypercarbia, or preexisting respiratory depression, particularly when initiating therapy and titrating therapy; critical respiratory depression may occur, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sleep-disordered breathing: Use opioids with caution for chronic pain and titrate dosage cautiously in patients with risk factors for sleep-disordered breathing, including HF and obesity. Avoid opioids in patients with moderate to severe sleep-disordered breathing (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with seizure disorders; may cause or exacerbate preexisting seizures. Some dosage forms may be contraindicated in patients with seizure disorder.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzodiazepines or other CNS depressants: [<b>US Boxed Warning]: Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of morphine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosage and durations to the minimum required and follow patients for signs and symptoms of respiratory depression and sedation.</b> Some dosage forms may be contraindicated in patients with acute alcoholism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ethanol use: Extended-release capsules:<b> [US Boxed Warning]: Patients should not consume alcoholic beverages or medication containing ethanol while taking ER capsules; ethanol may increase morphine plasma levels, resulting in a potentially fatal overdose.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cachectic or debilitated patients: Use with caution in cachectic or debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages. Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; may be more sensitive to adverse effects, including life-threatening respiratory depression. Decrease initial dose. In the setting of chronic pain, monitor closely due to an increased potential for risks, including certain risks such as falls/fracture, cognitive impairment, and constipation. Clearance may also be reduced in older adults (with or without renal impairment) resulting in a narrow therapeutic window and increasing the risk for respiratory depression or overdose (Dowell [CDC 2016]). Consider the use of alternative nonopioid analgesics in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Neonatal withdrawal syndrome: <b>[US Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.</b> Signs and symptoms include irritability, hyperactivity, abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight. Onset, duration, and severity depend on the drug used, duration of use, maternal dose, and rate of drug elimination by the newborn.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Infants &lt;3 months  of age, especially if premature, are more susceptible to respiratory depression and/or apnea; use with caution and generally in reduced doses in this age group (APS 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infumorph, Duramorph: Neuroaxial administration: <b>[US Boxed Warning]: </b><b>Because of the risk of severe adverse effects when the epidural or intrathecal route of administration is employed, patients must be observed in a fully equipped and staffed environment for at least 24 hours after the initial dose. Single-dose Duramorph neuraxial administration may result in acute or delayed respiratory depression for up to 24 hours. Monitor patients receiving Infumorph for the first several days after catheter implantation. </b>Naloxone injection should be immediately available. Thoracic epidural administration has been shown to dramatically increase the risk of early and late respiratory depression. High doses (&gt; 20 mg/day) of neuraxial morphine may produce myoclonic events.  Patients with reduced circulating blood volume or impaired myocardial function, or on concomitant sympatholytic drugs should be monitored for orthostatic hypotension, a frequent complication in single-dose neuraxial morphine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release formulations: Therapy should only be prescribed by health care professionals familiar with the use of potent opioids for chronic pain. Extended-release products are not interchangeable. When determining a generic equivalent or switching from one extended-release product to another, a thorough understanding of the pharmacokinetic properties is important in determining the proper generic equivalent or proper dose of the other extended-release product (review of the manufacturer's label may be necessary).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">-<i> Arymo ER: </i>Moistened tablets may become sticky, leading to difficulty in swallowing the tablets; choking, gagging, regurgitation, and tablets getting stuck in the throat may occur. Tablet stickiness and swelling may also predispose patients to intestinal obstruction and exacerbation of diverticulitis. Do not to pre-soak, lick, or otherwise wet tablets prior to placing in the mouth; take one tablet at a time with enough water to ensure complete swallowing. Consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying GI disorders resulting in a small GI lumen (eg, esophageal cancer, colon cancer).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- <i>Avinza capsules:</i> Dosage form contains fumaric acid; dangerous quantities of fumaric acid may be ingested when &gt;1,600 mg/day is used. Serious renal toxicity may occur above the maximum dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral solution: Risk of medication errors: <b>[US Boxed Warning]: </b><b>Ensure accuracy when prescribing, dispensing, and administering morphine oral solution. Dosing errors due to confusion between mg and mL, and other morphine solutions of different concentrations, can result in accidental overdose and death.</b> The 100 mg per 5 mL (20 mg/mL) is for use in opioid-tolerant patients only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injections: <b>[US Boxed Warning]: </b><b>Because of delay in maximum CNS effect with IV administration (30 minutes), rapid IV administration may result in overdosing. Observe patients in a fully equipped and staffed environment for at least 24 hours after each test dose of Infumorph and, as indicated, for the first several days after surgery. </b> Products are designed for administration by specific routes (ie, IV, intrathecal, epidural). Use caution when prescribing, dispensing, or administering to use formulations only by intended route(s). Rapid IV administration may result in chest wall rigidity. Use with caution when injecting IM into chilled areas or in patients with hypotension or shock (impaired perfusion may prevent complete absorption); if repeated injections are administered, an excessive amount may be suddenly absorbed if normal circulation is re-established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infumorph: Should only be used in microinfusion devices; not for IV, IM, or SubQ administration or for single-dose administration. Administer intrathecal doses of 10 and 25 mg/mL to the lumbar area. Monitor closely, especially in the first 24 hours. Inflammatory masses (eg, granulomas), some resulting in severe neurologic impairment, have occurred when receiving Infumorph via indwelling intrathecal catheter; monitor carefully for new neurologic signs/symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchange: Improper or erroneous substitution of Infumorph for regular Duramorph is likely to result in serious overdosage, leading to seizures, respiratory depression, and possibly a fatal outcome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sulfites: Some dosage forms may contain sulfites that may cause allergic reactions in sulfite sensitive patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse/misuse/diversion: <b>[US Boxed Warning]: Morphine exposes patients and other users to the risks of addiction, abuse, and misuse, potentially leading to overdose and death. Assess each patient&rsquo;s risk prior to prescribing; monitor all patients regularly for development of these behaviors or conditions.</b> Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Other factors associated with increased risk include younger age, concomitant depression (major), and psychotropic medication use. Consider offering naloxone prescriptions in patients with factors associated with an increased risk for overdose, such as history of overdose or substance use disorder, higher opioid dosages (&ge;50 morphine milligram equivalents/day orally), and concomitant benzodiazepine use (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Accidental exposure: Oral: formulations: <b>[US Boxed Warning]: Accidental ingestion of even one dose, especially in children, can result in a fatal overdose of morphine.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Chronic pain (outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder) in outpatient setting in adults: Opioids should <b>not</b> be used as first-line therapy for chronic pain management (pain &gt;3-month duration or beyond time of normal tissue healing) due to limited short-term benefits, undetermined long-term benefits, and association with serious risks (eg, overdose, MI, auto accidents, risk of developing opioid use disorder).  Preferred management includes nonpharmacologic therapy and nonopioid therapy (eg, NSAIDS, acetaminophen, certain anticonvulsants and antidepressants). If opioid therapy is initiated, it should be combined with nonpharmacologic and nonopioid therapy, as appropriate. Prior to initiation, known risks of opioid therapy should be discussed and realistic treatment goals for pain/function should be established, including consideration for discontinuation if benefits do not outweigh risks. Therapy should be continued only if clinically meaningful improvement in pain/function outweighs risks.  Therapy should be initiated at the lowest effective dosage using immediate-release opioids (instead of extended-release/long-acting opioids). Risk associated with use increases with higher opioid dosages.  Risks and benefits should be re-evaluated when increasing dosage to &ge;50 morphine milligram equivalents (MME)/day orally; dosages &ge;90 MME/day orally should be avoided unless carefully justified (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Optimal regimen: An opioid-containing analgesic regimen should be tailored to each patient's needs and based upon the type of pain being treated (acute versus chronic), the route of administration, degree of tolerance for opioids (naive versus chronic user), age, weight, and medical condition. The optimal analgesic dose varies widely among patients; doses should be titrated to pain relief/prevention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Opioids decrease bowel motility; monitor for decreased bowel motility in postop patients receiving opioids. Use with caution in the perioperative setting; individualize treatment when transitioning from parenteral to oral analgesics. Some dosage forms may be contraindicated after biliary tract surgery, suspected surgical abdomen, or surgical anastomosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Concurrent use of mixed agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol) or partial agonist (eg, buprenorphine) analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy in patients following prolonged therapy with mu opioid agonists. Taper dose gradually when discontinuing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776734\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), P-glycoprotein/ABCB1, UGT1A1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776735\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9788&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alvimopan: Opioid Analgesics may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May enhance the analgesic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiplatelet Agents (P2Y12 Inhibitors): Morphine (Systemic) may diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). Morphine (Systemic) may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors).  Management: Consider alternative anti-ischemic/analgesic therapies (eg, beta-blockers, nitroglycerin) in patients with acute coronary syndromes treated with a P2Y12 inhibitor when possible. The risks associated with other opioids are unknown.<b> Exceptions: </b>Cangrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics. Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Opioid Analgesics may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Opioid Analgesics may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esmolol: Morphine (Systemic) may increase the serum concentration of Esmolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gabapentin: May enhance the CNS depressant effect of Morphine (Systemic). Morphine (Systemic) may increase the serum concentration of Gabapentin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Morphine (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: May diminish the therapeutic effect of Opioid Analgesics. Management: Avoid the concomitant use of nalmefene and opioid analgesics. Discontinue nalmefene 1 week prior to any anticipated use of opioid analgesics. If combined, larger doses of opioid analgesics will likely be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naltrexone: May diminish the therapeutic effect of Opioid Analgesics. Management: Seek therapeutic alternatives to opioids.  See full drug interaction monograph for detailed recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Mixed Agonist / Antagonist): May diminish the analgesic effect of Opioid Analgesics. Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: Opioid Analgesics may diminish the therapeutic effect of Pegvisomant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Opioid Analgesics may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Morphine (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Opioid Analgesics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: May enhance the bradycardic effect of Opioid Analgesics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776739\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ethanol: Alcoholic beverages or ethanol-containing products may disrupt extended release formulation resulting in rapid release of entire morphine dose. Management: Avoid alcohol. <b>Do not administer Avinza or Kadian with alcoholic beverages or ethanol-containing prescription or nonprescription products.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Food: Administration of oral morphine solution with food may increase bioavailability (ie, a report of 34% increase in morphine AUC when morphine oral solution followed a high-fat meal). The bioavailability of Avinza, MorphaBond, MS Contin, or Kadian does not appear to be affected by food. Management: Take consistently with or without meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776700\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Prolonged maternal use of opioids during pregnancy can cause neonatal withdrawal syndrome in the newborn, which may be life-threatening if not recognized and treated according to protocols developed by neonatology experts. If prolonged opioid therapy is required in a pregnant woman, ensure treatment is available and warn patient of risk to the neonate.</b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Morphine crosses the placenta. Maternal use of opioids may be associated with birth defects, poor fetal growth, stillbirth, and preterm delivery (CDC [Dowell 2016]). If chronic opioid exposure occurs in pregnancy, adverse events in the newborn (including withdrawal) may occur (Chou 2009). Symptoms of neonatal abstinence syndrome (NAS) following opioid exposure may be autonomic (eg, fever, temperature instability), gastrointestinal (eg, diarrhea, vomiting, poor feeding/weight gain), or neurologic (eg, high-pitched crying, hyperactivity, increased muscle tone, increased wakefulness/abnormal sleep pattern, irritability, sneezing, seizure, tremor, yawning) (Dow 2012; Hudak 2012). Mothers who are physically dependent on opioids may give birth to Infants who are also physically dependent. Opioids may cause respiratory depression and psycho-physiologic effects in the neonate; newborns of mothers receiving opioids during labor should be monitored.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Morphine is commonly used for the treatment of pain during labor and immediately postpartum (ACOG 177 2017). Not all preparations are recommended for use and morphine should not be used when other analgesic techniques are more appropriate. Agents other than morphine are used to treat chronic non-cancer pain in pregnant women or those who may become pregnant (CDC [Dowell 2016]; Chou 2009; Kahan 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776703\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Morphine is present in breast milk. M6G, the active metabolite of morphine, can also be detected in breast milk (Baka 2002). Reported concentrations of morphine in breast milk are variable.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Morphine has been detected in the urine of a breastfeeding infant following maternal epidural dosing after cesarean section (Zakowski 1993) and the serum of an infant following chronic maternal oral use (Robieux 1990).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Current guidelines note that nonopioid analgesics are preferred for postpartum pain in breastfeeding women (Montgomery 2012); however, when a narcotic is needed to treat maternal pain, morphine is one of the preferred agents (Montgomery 2012; Sachs 2013). Analgesics delivered by PCA or administered by the epidural route help limit infant exposure (Sachs 2013). When intravenous or intramuscular opioids are needed, moderate to low doses of parenteral morphine may be preferred (Montgomery 2012). <b>Note:</b> Not all formulations are indicated for intermittent pain control.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When opioids are needed in breastfeeding women, the lowest effective dose for the shortest duration of time should be used to limit adverse events in the mother and breastfeeding infant. In general, a single occasional dose of an opioid analgesic may be compatible with breastfeeding (WHO 2002). Breastfeeding women using opioids for postpartum pain or for the treatment of chronic maternal pain should monitor their infants for drowsiness, sedation, feeding difficulties, or limpness (ACOG 177 2017; Montgomery 2012; Sachs 2013). Withdrawal symptoms may occur when maternal use is discontinued or breastfeeding is stopped.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776886\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Morphine may cause GI upset; take with food if GI upset occurs. Be consistent when taking morphine with or without meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776892\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pain control, respiratory and mental status; blood pressure; signs of misuse, abuse, and addiction; signs or symptoms of hypogonadism or hypoadrenalism (Brennan 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alternate recommendations: Chronic pain (long-term therapy outside of end-of-life or palliative care, active cancer treatment, sickle cell disease, or medication-assisted treatment for opioid use disorder): Evaluate benefits/risks of opioid therapy within 1 to 4 weeks of treatment initiation and with dose increases. Re-evaluate benefits/risks every 3 months during therapy or more frequently in patients at increased risk of overdose or opioid use disorder. Urine drug testing is recommended prior to initiation and with consideration for re-checking at least yearly (includes controlled prescription medications and illicit drugs of abuse). State prescription drug monitoring program (PDMP) data should be reviewed by clinicians prior to initiation and periodically during therapy (frequency ranging from every prescription to every 3 months) (Dowell [CDC 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epidural/intrathecal: Patients should be observed in a fully equipped and staffed environment for at least 24 hours following initiation, and as appropriate for the first several days after catheter implantation. Naloxone injection should be immediately available. Patient should remain in this environment for at least 24 hours following the initial dose. For patients receiving Infumorph via microinfusion device, patient may be observed, as appropriate, for the first several days after catheter implantation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Alternative monitoring recommendations</i></b> (Bujedo 2012): Epidural: <b>Note:</b> All patients receiving neuraxial opioids should be monitored for adequate ventilation (eg, respiratory rate, depth of respiration [without disturbing patient]), oxygenation (eg, pulse oximetry when appropriate), and level of consciousness.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Single dose:</i> Monitor patient for a minimum of 24 hours after administration with a frequency of at least once per hour for the first 12 hours after administration, followed by at least once every 2 hours for the next 12 hours (ie, from 12 to 24 hours after administration). After 24 hours, frequency dictated by overall clinical condition and concurrent medications.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Continuous infusion or patient controlled epidural analgesia (PCEA):</i> Monitor patient during the entire duration of the infusion with a frequency of at least once per hour for the first 12 hours, followed by at least once every 2 hours for the next 12 hours (ie, from 12 to 24 hours after administration). After 24 hours, monitor at least once every 4 hours. After discontinuation of infusion or PCEA, frequency dictated by overall clinical condition and concurrent medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Also refer to institution specific protocols as appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776768\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to opioid receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776772\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action (patient dependent; dosing must be individualized): Oral (immediate release): ~30 minutes; IV: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration (patient dependent; dosing must be individualized): Pain relief:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate-release formulations (tablet, oral solution, injection): 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Extended-release capsule and tablet: 8 to 24 hours (formulation dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epidural or intrathecal: Single dose: Up to 24 hours (Bujedo 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Suppository: 3 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Variable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes to skeletal muscle, liver, kidneys, lungs, intestinal tract, spleen and brain; V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancer patients (children age: 1.7 to 18.7 years): Median: 5.2 L/kg; a significantly higher V<sub>d</sub> was observed in children &lt;11 years (median: 7.1 L/kg) versus &gt;11 years (median: 4.7 L/kg) (Hunt 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1 to 6 L/kg; binds to opioid receptors in the CNS and periphery (eg, GI tract)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Premature Infants: &lt;20%; Adults: 20% to 35%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via conjugation with glucuronic acid primarily to morphine-6-glucuronide (M6G) (active analgesic) morphine-3-glucuronide (M3G) (inactive as analgesic; may contribute to CNS stimulation [Lugo 2002]); minor metabolites include morphine-3-6-diglucuronide; other minor metabolites include normorphine (active) and morphine 3-ethereal sulfate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 17% to 33% (first-pass effect limits oral bioavailability; oral:parenteral effectiveness reportedly varies from 1:6 in opioid-naive patients to 1:3 with chronic use); Nebulization: 5.5 &plusmn; 3.2% (Masood 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm: 10 to 20 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 7.6 hours (range: 4.5 to 13.3 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 1 to 3 months: Median: 6.2 hours (range: 5 to 10 hours) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 3 to 6 months: Median: 4.5 hours (range: 3.8 to 7.3 hours) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 6 months to Children 2.5 years: Median: 2.9 hours (range: 1.4 to 7.8 hours) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preschool Children: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children with sickle cell disease (age: 6 to 19 years): ~1.3 hours (Dampier 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Immediate-release forms: 2 to 4 hours; Avinza: ~24 hours;  Kadian: 11 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Plasma:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tablets, oral solution, epidural: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Extended release tablets: 3 to 4 hours; Avinza: 30 minutes (maintained for 24 hours); Kadian: ~10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Suppository: 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">SubQ: 50 to 90 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cerebrospinal fluid: After an oral dose of controlled release morphine concentrations peak at 8 hours for both normal and reduced renal function; morphine-6-glucuronide (active analgesic) and morphine-3-glucuronide distribution into the CNS may be delayed peaking at 12 hours in patients with normal renal function or up to 24 hours in patients with ESRD (peak level of morphine-6-glucuronide is ~15 times higher than patients with normal renal function) (D'Honneur 1994).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily as morphine-3-glucuronide, neonates: 3% to 15%; adults: ~2% to 12% excreted unchanged); feces (~7% to 10%). It has been suggested that accumulation of morphine-6-glucuronide might cause toxicity with renal insufficiency. All of the metabolites (ie, morphine-3-glucuronide, morphine-6-glucuronide, and normorphine) have been suggested as possible causes of neurotoxicity (eg, myoclonus).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: <b>Note:</b> In pediatric patients, adult values are reached by 6 months to 2.5 years of age (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm: 0.5 to 3 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates 1 to 7 days: Median: 5.5 mL/minute/kg (range: 3.2 to 8.4 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates 8 to 30 days: Median: 7.4 mL/minute/kg (range: 3.4 to 13.8 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 1 to 3 months: Median: 10.5 mL/minute/kg (range: 9.8 to 20.1 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 3 to 6 months: Median: 13.9 mL/minute/kg (range: 8.3 to 24.1 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants 6 months to Children 2.5 years: Median: 21.7 mL/minute/kg (range: 5.8 to 28.6 mL/minute/kg) (McRorie 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preschool Children: 20 to 40 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancer patients (Children age 1.7 to 18.7 years): Median: 23.1 mL/minute/kg; a significantly higher clearance was observed in children &lt;11 years (median: 37.4 mL/minute/kg) versus &gt;11 years (median: 21.9 mL/minute/kg) (Hunt 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children with sickle cell disease (age: 6 to 19 years): ~36 mL/minute/kg (range: 6 to 59 mL/minute/kg) (Dampier 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 20 to 30 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8776910\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Kadian Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $697.07</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $769.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (60): $837.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (60): $1,117.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (60): $1,400.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (60): $1,675.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (60): $2,232.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (60): $2,753.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (60): $5,657.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Morphine Sulfate ER Beads Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $572.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (100): $849.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,112.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $1,415.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $1,672.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $1,973.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Morphine Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $283.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $522.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $568.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $950.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,137.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (100): $1,515.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $1,900.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Device</b> (Morphine Sulfate Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.7 mL (0.7 mL): $31.45</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Infumorph 200 Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 MG/20ML (10 mg/mL) (20 mL): $237.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Infumorph 500 Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 MG/20ML (25 mg/mL) (20 mL): $404.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate (Concentrate) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (30 mL): $25.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/mL (10 mL): $7.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (10 mL): $8.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $2.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $2.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/mL (1 mL): $2.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $2.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 5% (100 mL): $16.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250MG/250ML 5% (250 mL): $19.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (1 mL): $3.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (30 mL): $9.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (10 mL): $8.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (20 mL): $13.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (100 mL): $12.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/5 mL (100 mL): $17.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/50 mL 0.9% (50 mL): $22.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/100 mL 0.9% (100 mL): $30.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Morphine Sulfate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL 0.9% (50 mL): $15.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $12.91</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150MG/150ML 0.9% (150 mL): $17.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250MG/250ML 0.9% (250 mL): $18.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 mg/100 mL 0.9% (100 mL): $24.67</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2500MG/250ML 0.9% (250 mL): $71.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Morphine Sulfate in Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50MG/25ML 5% (25 mL): $9.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Morphine Sulfate-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/mL 0.9% (1 mL): $8.15</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2MG/2ML 0.9% (2 mL): $5.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Morphine Sulfate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2MG/2ML 0.9% (2 mL): $4.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5MG/5ML 0.9% (5 mL): $5.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/50 mL 0.9% (50 mL): $11.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60MG/30ML 0.9% (30 mL): $11.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150MG/30ML 0.9% (30 mL): $11.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">275MG/55ML 0.9% (55 mL): $12.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Morphine Sulfate Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (12): $60.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (12): $75.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (12): $90.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (12): $112.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet ER 12 Hour Abuse-Deterrent</b> (MorphaBond ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $648.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,296.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $2,037.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $3,396.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Extended Release Abuse-Deterrent</b> (Arymo ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $569.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,140.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $2,281.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Morphine Sulfate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $167.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $317.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $621.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $919.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $1,838.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (MS Contin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $433.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $823.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,606.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $2,378.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (100): $4,355.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Morphine Sulfate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (100): $43.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $74.71</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961991\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anamorph (AU);</li>\n      <li>Contalgin (DK, IS);</li>\n      <li>Depolan (FI);</li>\n      <li>Dimorf (BR);</li>\n      <li>Dimorf SP (PY);</li>\n      <li>Dolcontin (FI, SE);</li>\n      <li>Dolcontin Depottab (NO);</li>\n      <li>Doltard (DK, EE, LV);</li>\n      <li>Graten (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Kadian (BM);</li>\n      <li>Kapanol (AU);</li>\n      <li>La Morph (NZ);</li>\n      <li>M-Eslon (CL, CO, EC, PE);</li>\n      <li>M.I.R. (IL);</li>\n      <li>MCR (IL);</li>\n      <li>Morfex (BD);</li>\n      <li>Morficontin (GR);</li>\n      <li>Morgesic XR (BD);</li>\n      <li>Morphanton (DE);</li>\n      <li>Morphgesic (TR);</li>\n      <li>Morphgesic SR (GB, MT);</li>\n      <li>Moscontin (FR);</li>\n      <li>MS Contin (AU, BE, CN, IT, LU, NL, VE);</li>\n      <li>MS Contin CR (KR);</li>\n      <li>MS Mono (AU);</li>\n      <li>MSP (IL);</li>\n      <li>MST (PT);</li>\n      <li>MST Continus (AE, AR, BF, BG, BH, BJ, CI, CY, CZ, EE, EG, ES, ET, GB, GH, GM, GN, HK, HR, ID, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, OM, PH, PK, PL, QA, RO, SA, SC, SD, SG, SK, SL, SN, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>MST Continus Retard (CH);</li>\n      <li>Mundidol Retard (AT);</li>\n      <li>MXL (TW);</li>\n      <li>Oramorph (BE, ES, FR, GB, IE, LU, PT, SE);</li>\n      <li>P Guard (JP);</li>\n      <li>Pacif (JP);</li>\n      <li>RA-Morph (NZ);</li>\n      <li>Rumorf (IN);</li>\n      <li>S-Morphine (KR);</li>\n      <li>Sevredol (AU, CH, CZ, HR, IE, NZ, RO, SI, SK, TR);</li>\n      <li>Statex (SG);</li>\n      <li>Vendal (AT, UY);</li>\n      <li>Vendal Retard (LV);</li>\n      <li>Vermor (LK);</li>\n      <li>Zomorph (ES)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists Number 36, July 2002. Obstetric Analgesia and Anesthesia,&quot; <i>Obstet Gynecol</i>, 2002, 100(1):177-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/12100826/pubmed\" target=\"_blank\" id=\"12100826\">12100826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins&mdash;Obstetrics. Practice bulletin no. 177: obstetric analgesia and anesthesia. <i>Obstet Gynecol</i>. 2017;129(4):e73-e89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/28333819/pubmed\" target=\"_blank\" id=\"28333819\">28333819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Acute Pain Management in Infants, Children, and Adolescents: Operative and Medical Procedures. Agency for Health Care Policy and Research,&quot; <i>Am Fam Physician</i>, 1992, 46(2):469-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/1636563/pubmed\" target=\"_blank\" id=\"1636563\">1636563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arymo ER (morphine) [prescribing information]. Wayne, PA: Egalet US Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Association of Paediatric Anaesthetists of Great Britain and Ireland (APA). Good practice in postoperative and procedural pain management, 2nd edition. <i>Paediatr Anaesth.</i> 2012;22(Suppl 1):1-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/22817132/pubmed\" target=\"_blank\" id=\"22817132\">22817132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Astramorph/PF (morphine sulfate) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals; June 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aubrun F, Mazoit JX, and Riou B, &ldquo;Postoperative Intravenous Morphine Titration,&rdquo; <i>Br J Anaesthesia</i>, 2012, 108(2):193-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/22250276/pubmed\" target=\"_blank\" id=\"22250276\">22250276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aubrun F, Monsel S, Langeron O, et al, &ldquo;Postoperative Titration of Intravenous Morphine in the Elderly Patient,&rdquo; <i>Anesthesiology</i>, 2002, 96(1):17-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/11752996/pubmed\" target=\"_blank\" id=\"11752996\">11752996</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avinza (morphine sulfate) [prescribing information]. Gainesville, GA: Alkermes Gainesville; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baka NE, Bayoumeu F, Boutroy MJ, Laxenaire MC. Colostrum morphine concentrations during postcesarean intravenous patient-controlled analgesia. <i>Anesth Analg</i>. 2002;94(1):184-187.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/11772825/pubmed\" target=\"_blank\" id=\"11772825\">11772825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo; <i>Pediatrics</i>, 1990, 86(5 Pt 2):818-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/2216644/pubmed\" target=\"_blank\" id=\"2216644\">2216644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde CB, Sethna NF. Analgesics for the treatment of pain in children [published correction appears in <i>N Engl J Med</i>. 2011;364(18):1782]. <i>N Engl J Med. </i>2002;347(14):1094-1103.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/12362012/pubmed\" target=\"_blank\" id=\"12362012\">12362012</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brennan MJ. The effect of opioid therapy on endocrine function. <i>Am J Med</i>. 2013;126(3) (Suppl 1):S12-S18. doi: 10.1016/j.amjmed.2012.12.001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/23414717/pubmed\" target=\"_blank\" id=\"23414717\">23414717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al, &quot;Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,&quot; <i>Neurology</i>, 2011, 76(20):1758-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunk SF and Delle M, &ldquo;Morphine Metabolism in Man,&rdquo; <i>Clin Pharmacol Ther</i>, 1974, 16(1):51-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/4843237/pubmed\" target=\"_blank\" id=\"4843237\">4843237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bujedo BM, &quot;A Clinical Approach to Neuroaxial Morphine for the Treatment of Postoperative Pain,&quot; <i>Pain Res Treat</i>, 2012, 8(3):177-92<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/23002426/pubmed\" target=\"_blank\" id=\"23002426\">23002426</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capogna G, Celleno D, Zangrillo A, et al, &ldquo;Addition of Clonidine to Epidural Morphine Enhances Postoperative Analgesia After Cesarean Delivery,&rdquo; <i>Reg Anesth</i>, 1995, 20(1):57-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/7727330/pubmed\" target=\"_blank\" id=\"7727330\">7727330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou R, Fanciullo GJ, Fine PG, et al, &ldquo;Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain,&rdquo; <i>J Pain</i>, 2009, 10(2):113-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/19187889/pubmed\" target=\"_blank\" id=\"19187889\">19187889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6205587\"></a>Citron ML, Johnston-Early A, Fossieck BE Jr, et al. Safety and efficacy of continuous intravenous morphine for severe cancer pain. <i>Am J Med</i>. 1984;77(2):199-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/6205587/pubmed\" target=\"_blank\" id=\"6205587\">6205587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cramton RE, Gruchala NE. Managing procedural pain in pediatric patients. <i>Curr Opin Pediatr</i>. 2012;24(4):530-538.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/22732639/pubmed\" target=\"_blank\" id=\"22732639\">22732639</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dampier CD, Setty BN, Logan J, et al, &ldquo;Intravenous Morphine Pharmacokinetics in Pediatric Patients With Sickle Cell Disease,&rdquo; <i>J Pediatr</i>, 1995, 126(3):461-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/7869211/pubmed\" target=\"_blank\" id=\"7869211\">7869211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D'Honneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. <i>Anesthesiology</i>. 1994;81(1):87-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/8042814/pubmed\" target=\"_blank\" id=\"8042814\">8042814</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dow K, Ordean A, Murphy-Oikonen J, et al, &quot;Neonatal Abstinence Syndrome Clinical Practice Guidelines For Ontario,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(3):e488-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/23241498/pubmed\" target=\"_blank\" id=\"23241498\">23241498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain&mdash;United States, 2016. <i>MMWR Recomm Rep</i>. 2016;65(1):1-49. doi: 10.15585/mmwr.rr6501e1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/26987082/pubmed\" target=\"_blank\" id=\"26987082\">26987082</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duramorph Preservative free (morphine sulfate injection) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedrichsdorf SJ and Kang TI, &ldquo;The Management of Pain in Children With Life-Limiting Illness,&rdquo; <i>Pediatr Clin N Am</i>, 2007, 54(5):645-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/17933616/pubmed\" target=\"_blank\" id=\"17933616\">17933616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gahart BL, Nazareno AR. <i>2014 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>. 30th ed. St Louis, MO: Elsevier/Mosby; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glare PA and Walsh TD, &ldquo;Clinical Pharmacokinetics of Morphine,&rdquo; <i>Ther Drug Monit</i>, 1991, 13(1):1-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/2057987/pubmed\" target=\"_blank\" id=\"2057987\">2057987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golianu B, Krane EJ, Galloway KS, et al, &ldquo;Pediatric Acute Pain Management,&rdquo; <i>Pediatr Clin North Am</i>, 2000, 47(3):559-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/10835991/pubmed\" target=\"_blank\" id=\"10835991\">10835991</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henneberg SW, Hole P, Madsen de Haas I, et al, &ldquo;Epidural Morphine for Postoperative Pain Relief in Children,&rdquo; <i>Acta Anaesthesiol Scand</i>, 1993, 37(7):664-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/8249555/pubmed\" target=\"_blank\" id=\"8249555\">8249555</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holdsworth MT, Adams VR, Chavez CM, et al, &ldquo;Continuous Midazolam Infusion for the Management of Morphine-Induced Myoclonus,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(1):25-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/7711342/pubmed\" target=\"_blank\" id=\"7711342\">7711342</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hudak ML, Tan RC, Committee On Drugs, et al, &quot;Neonatal Drug Withdrawal,&quot; <i>Pediatrics</i>, 2012, 129(2):e540-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/22291123/pubmed\" target=\"_blank\" id=\"22291123\">22291123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt A, Joel S, Dick G, et al, &ldquo;Population Pharmacokinetics of Oral Morphine and Its Glucuronides in Children Receiving Morphine as Immediate-Release Liquid or Sustained-Release Tablets for Cancer Pain,&rdquo; <i>J Pediatr</i>, 1999, 135(1):47-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/10393603/pubmed\" target=\"_blank\" id=\"10393603\">10393603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Infumorph (morphine sulfate injection) [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP), &ldquo;Beware of Basal Opioid Infusions With PCA Therapy,&rdquo; 2009. Available at https://www.ismp.org/Newsletters/acutecare/articles/20090312.asp</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    June HL, Stitzer ML, and Cone E, &ldquo;Acute Physical Dependence: Time Course and Relation to Human Plasma Morphine Concentrations,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 57(3):270-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/7697945/pubmed\" target=\"_blank\" id=\"7697945\">7697945</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadian (morphine sulfate) [prescribing information]. Irvine, CA: Allergan USA Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kahan M, Wilson L, Mailis-Gagnon A, et al, &quot;Canadian Guideline For Safe and Effective Use of Opioids For Chronic Noncancer Pain: Clinical Summary For Family Physicians. Part 2: Special Populations,&quot; <i>Can Fam Physician</i>, 2011, 57(11):1269-76, e419-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/22084456/pubmed\" target=\"_blank\" id=\"22084456\">22084456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaiko RF, &ldquo;Age and Morphine Analgesia in Cancer Patients With Postoperative Pain,&rdquo; <i>Clin Pharmacol Ther</i>, 1980, 28(6):823-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/7438698/pubmed\" target=\"_blank\" id=\"7438698\">7438698</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. Nelson Textbook of Pediatrics. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugo RA, Kern SE. Clinical pharmacokinetics of morphine. <i>J Pain Palliat Care Pharmacother</i>. 2002;16(4):5-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/14635822/pubmed\" target=\"_blank\" id=\"14635822\">14635822</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lvovschi V, Aubrun F, Bonnet P, et al, &ldquo;Intravenous Morphine Titration to Treat Severe Pain in the ED,&rdquo; <i>Am J Emerg Med</i>, 2008, 26(6):676-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/18606320/pubmed\" target=\"_blank\" id=\"18606320\">18606320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahoney OM, Noble PC, Davidson J, Tullos HS. The effect of continuous epidural analgesia on postoperative pain, rehabilitation, and duration of hospitalization in total knee arthroplasty. <i>Clin Orthop Relat Res</i>. 1990;(260):30-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/1977542/pubmed\" target=\"_blank\" id=\"1977542\">1977542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masood AR and Thomas SH, &quot;Systemic Absorption of Nebulized Morphine Compared With Oral Morphine in Healthy Subjects,&quot; <i>Br J Clin Pharmacol</i>, 1996, 41(3):250-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/8866928/pubmed\" target=\"_blank\" id=\"8866928\">8866928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McRorie TI, Lynn AM, Nespeca MK, et al, &ldquo;The Maturation of Morphine Clearance and Metabolism,&rdquo; <i>Am J Dis Child</i>, 1992, 147(8):972-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/1636668/pubmed\" target=\"_blank\" id=\"1636668\">1636668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meine TJ, Roe MT, Chen AY, et al, &ldquo;Association of Intravenous Morphine Use and Outcomes in Acute Coronary Syndromes: Results From the CRUSADE Quality Improvement Initiative,&rdquo; <i>Am Heart J</i>, 2005, 149(6):1043-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/15976786/pubmed\" target=\"_blank\" id=\"15976786\">15976786</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mignault GG, Latreille J, Viguie F, et al, &ldquo;Control of Cancer-Related Pain With MS Contin: A Comparison Between 12-Hourly and 8-Hourly Administration,&rdquo; <i>J Pain Symptom Manage</i>, 1995, 10(6):416-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/7561223/pubmed\" target=\"_blank\" id=\"7561223\">7561223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molitch ME. Drugs and prolactin. <i>Pituitary</i>. 2008;11(2):209-218.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/18404390/pubmed\" target=\"_blank\" id=\"18404390\">18404390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery A, Hale TW, and Academy of Breastfeeding Medicine, &quot;ABM Clinical Protocol #15: Analgesia and Anesthesia for the Breastfeeding Mother, Revised 2012,&quot; <i>Breastfeed Med</i>, 2012, 7(6):547-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/23215911/pubmed\" target=\"_blank\" id=\"23215911\">23215911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morphabond ER (morphine sulfate) [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morphine sulfate oral solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morphine sulfate tablet [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MS Contin (morphine sulfate) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MS Contin (morphine sulfate) [prescribing information]. Stamford, CT: Purdue Pharma; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Niscola P, Scaramucci L, Vischini G, et al. The use of major analgesics in patients with renal dysfunction. <i>Curr Drug Targets</i>. 2010;11(6):752-758.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/20041843/pubmed\" target=\"_blank\" id=\"20041843\">20041843</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olkkola KT, Hamunen K, and Maunuksela EL, &ldquo;Clinical Pharmacokinetics and Pharmacodynamics of Opioid Analgesics in Infants and Children,&rdquo; <i>Clin Pharmacokinet</i>, 1995, 28(5):385-404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/7614777/pubmed\" target=\"_blank\" id=\"7614777\">7614777</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rathmell JP, Lair TR, and Nauman B, &ldquo;The Role of Intrathecal Drugs in the Treatment of Acute Pain,&rdquo; <i>Anesth Analg</i>, 2005, 101(5 Suppl):30-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/16334491/pubmed\" target=\"_blank\" id=\"16334491\">16334491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robieux I, Koren G, Vandenbergh H, Schneiderman J. Morphine excretion in breast milk and resultant exposure of a nursing infant. <i>J Toxicol Clin Toxicol</i>. 1990;28(3):365-370.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/2231835/pubmed\" target=\"_blank\" id=\"2231835\">2231835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/23979084/pubmed\" target=\"_blank\" id=\"23979084\">23979084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sauberan J, Rossi S, Kim JH. Stability of dilute oral morphine solution for neonatal abstinence syndrome. <i>J Addict Med</i>. 2013;7(2):113-115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/23370932/pubmed\" target=\"_blank\" id=\"23370932\">23370932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinclair-Pingel J, Grisso AG, Hargrove FR, Wright L. Implementation of standardized concentrations for continuous infusions using a computerized provider Oder Entry System [published correction appears in <i>Hosp Pharm</i>. 2007;42:84-85]. <i>Hosp Pharm</i>. 2006;41(11):1102-1106.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spigset O and Hagg S, &ldquo;Analgesics and Breast-feeding: Safety Considerations,&rdquo; <i>Paediatr Drugs</i>, 2000, 2(3):223-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/10937472/pubmed\" target=\"_blank\" id=\"10937472\">10937472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sultan P, Gutierrez MC, and Carvalho B, &ldquo;Neuraxial Morphine and Respiratory Depression: Finding the Right Balance,&rdquo; <i>Drugs</i>, 2011, 71(14):1807-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/21942973/pubmed\" target=\"_blank\" id=\"21942973\">21942973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. <i>Endocr Rev</i>. 2010;31(1):98-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/19903933/pubmed\" target=\"_blank\" id=\"19903933\">19903933</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zacher JL and Givone DM, &ldquo;False-Positive Urine Opiate Screening Associated With Fluoroquinolone Use,&rdquo; <i>Ann Pharmacother</i>, 2004, 38:1525-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/15252190/pubmed\" target=\"_blank\" id=\"15252190\">15252190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zakowski MI, Ramanathan S, Turndorf H. A two-dose epidural morphine regimen in cesarean section patients: pharmacokinetic profile. <i>Acta Anaesthesiol Scand</i>. 1993;37(6):584-589.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/8213024/pubmed\" target=\"_blank\" id=\"8213024\">8213024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeltzer LK, Altman A, Cohen D, LeBaron S, Munuksela EL, Schechter NL. American Academy of Pediatrics report of the subcommittee on the management of pain associated with procedures in children with cancer. <i>Pediatrics</i>. 1990;86(5 Pt 2):826-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/morphine-drug-information/abstract-text/2216645/pubmed\" target=\"_blank\" id=\"2216645\">2216645</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9788 Version 297.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50711535\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F8775511\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8776636\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8776637\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8776648\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8776811\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F8776810\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8776812\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F8776813\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F8776814\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8776907\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8776646\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F8776908\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F8776634\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9845085\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8776887\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472937\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472938\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8776698\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8775520\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8776722\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8776704\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8776705\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8776734\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8776735\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F8776739\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8776700\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F8776703\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F8776886\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F8776892\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8776768\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8776772\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8776910\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961991\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9788|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=morphine-patient-drug-information\" class=\"drug drug_patient\">Morphine: Patient drug information \t</a></li><li><a href=\"topic.htm?path=morphine-pediatric-drug-information\" class=\"drug drug_pediatric\">Morphine: Pediatric drug information</a></li></ul></div></div>","javascript":null}